Technetium-99m Market Report 2026

Technetium-99m Market Overview

• Technetium-99m market size has reached to $4.75 billion in 2025 • Expected to grow to $6.01 billion in 2030 at a compound annual growth rate (CAGR) of 4.8% • Growth Driver: Increasing Demand For Diagnostic Imaging Procedures Fueling The Growth Of The Market Due To Rising Prevalence Of Chronic Diseases • Market Trend: Innovative Radiopharmaceutical Imaging Agents Enhancing Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Technetium-99m Market?

Technetium-99m (Tc-99m) refers to a radioactive isotope of technetium used widely in nuclear medicine for diagnostic imaging. It emits gamma rays detectable by a gamma camera, allowing visualization of internal organs and structures. Tc-99m has a short half-life of about 6 hours, which minimizes radiation exposure to the patient while providing clear imaging results. The main products of technetium-99m are radiopharmaceuticals, diagnostic kits, and generators. Radiopharmaceuticals refer to radioactive compounds used for diagnosis or treatment in medical imaging and therapy. The multiple formulation types involved are liquid, solid, and freeze-dried. The various applications include single photon emission computed tomography (SPECT) imaging, positron emission tomography (PET) imaging, oncology, cardiology, neurology, and others, and cater to several end users such as hospitals, diagnostic imaging centers, research laboratories, specialized clinics, and others.

What Is The Technetium-99m Market Growth Forecast?

The technetium-99m market size is expected to see steady growth in the next few years. It will grow to $6.01 billion in 2030 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, expansion of hospital and imaging center networks, development of novel Tc-99m radiopharmaceuticals, integration of ai in nuclear imaging, rising awareness for early disease detection. Major trends in the forecast period include increased adoption of spect imaging, growth in cardiac and oncology diagnostics, short half-life radiopharmaceutical demand, expansion of centralized radiopharmacy services, regulatory compliance and safety enhancements.

Global Technetium-99m Market Segmentation

1) By Product Type: Radiopharmaceuticals, Diagnostic Kits, Generators 2) By Formulation Type: Liquid, Solid, Freeze-Dried 3) By Application: Single Photon Emission Computed Tomography (SPECT) Imaging, Oncology, Cardiology, Neurology, Other Applications 4) By End-User: Hospitals, Diagnostic Imaging Centers, Research Laboratories, Specialized Clinics, Other End-Users Subsegments: 1) By Radiopharmaceuticals: Sestamibi, Tetrofosmin, Sulfur Colloid, MAA (Macroaggregated Albumin), DTPA (Diethylenetriaminepentaacetic Acid) 2) By Diagnostic Kits: Cardiac Imaging Kits, Bone Imaging Kits, Renal Imaging Kits, Hepatobiliary Imaging Kits, Pulmonary Imaging Kits 3) By Generators: Hospital-Based Generators, Centralized Radiopharmacy Generators

What Is The Driver Of The Technetium-99m Market?

The increasing demand for diagnostic imaging procedures is expected to propel the growth of the technetium-99m market going forward. Diagnostic imaging procedures refer to medical techniques used to create visual representations of the interior of the body and help doctors to diagnose and sometimes guide treatment for various medical conditions. The increasing demand for diagnostic imaging procedures is due to the rising prevalence of chronic diseases requiring early and accurate diagnosis. Technetium-99m helps diagnostic imaging procedures by allowing doctors to visualize the function of organs and tissues with high precision, using its radioactive properties to produce detailed images in nuclear medicine scans. For instance, in November 2023, according to the National Health Service (NHS) England, a UK-based government department, in the year leading up to March 2023, 45.0 million imaging tests were conducted in England, marking a 2.2% increase from the 44.0 million tests performed in the previous year. Therefore, the increasing demand for diagnostic imaging procedures is driving the growth of the technetium-99m industry.

Key Players In The Global Technetium-99m Market

Major companies operating in the technetium-99m market are Cardinal Health Inc, GE Healthcare Technologies Inc, BWX Technologies Inc, Bracco Imaging S p A, Lantheus Holdings Inc, China Isotope And Radiation Corporation, Jubilant Pharma Limited, Curium Pharma LLC, Eckert And Ziegler Strahlen, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Isotopia Molecular Imaging Ltd, Cyclopharm Limited, SHINE Technologies LLC, Medi Radiopharma Kft, SDS Lifesciences Pvt Ltd, ANSTO Nuclear Medicine, IRE ELiT, Sam Young Unitech Co Ltd, RadioMedix Inc, Institute Of Isotopes Co Ltd, Monrol Nuclear Products

Global Technetium-99m Market Trends and Insights

Major companies operating in the technetium-99m market are focusing on developing innovative solutions, such as advanced radiopharmaceutical imaging agents, to enhance the accuracy and accessibility of diagnostic imaging procedures for complex medical conditions. Advanced radiopharmaceutical imaging agents refer to special compounds labeled with radioactive materials that help doctors see inside the body using imaging techniques. For instance, in June 2024, Serac Healthcare Limited, a UK-based clinical radiopharmaceutical company, received Fast Track Designation from the US Food and Drug Administration (FDA) for 99mTc-maraciclatide, an innovative single-photon emission computed tomography (SPECT)-computed tomography (CT) imaging agent for the visualization and diagnosis of superficial peritoneal endometriosis in women aged 16 years and older. 99mTc-maraciclatide is a technetium-99m-labeled targeted peptide imaging agent that binds to integrins overexpressed in endometriosis lesions, enabling clear visualization of disease sites during SPECT-CT scans. It offers a non-invasive diagnostic alternative to laparoscopic procedures, providing women with suspected endometriosis a safer and more accessible diagnostic pathway. The agent leverages the favorable imaging properties of technetium-99m, including its ideal half-life and gamma emission energy, to deliver high-quality diagnostic images while minimizing patient radiation exposure. This innovation is poised to enhance diagnostic accuracy and streamline treatment decisions in endometriosis management while expanding the clinical applications of technetium-99m-based imaging in women’s health.

What Are Latest Mergers And Acquisitions In The Technetium-99m Market?

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired ARTMS Inc. for an undisclosed amount. Through this acquisition, Telix aims to enhance its control over the supply chain for key medical isotopes, including technetium-99m, by integrating ARTMS’s cyclotron-based radioisotope production technology and intends to support the large-scale, cost-effective, and reliable production of diagnostic and therapeutic isotopes for Telix’s radiopharmaceutical portfolio. ARTMS Inc. is a Canada-based novel radioisotope technology and products company specializing in advanced cyclotron technologies to produce medical radioisotopes such as technetium-99m.

Regional Outlook

North America was the largest region in the technetium-99m market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Technetium-99m Market?

The technetium-99m market includes revenues earned by entities by providing services such as diagnostic imaging, functional imaging, medical diagnostic imaging, cardiac imaging, and cancer detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The technetium-99m market also includes sales of technetium-99m sestamibi, mercaptoacetyltriglycine, hexamethylpropyleneamine oxime, technetium-99m pertechnetate, and diethylenetriamine pentaacetic acid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.